SBIR/STTR Research Award

Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine

Award identifier 352eee76e1d802059ee762707c9fc56f6be813758e4d855b5e993180b00cdb5bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$993,957

Program and phase

STTR · Phase II

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
490 BIOTECH INC
Proposal award date
2017-09-01
Contract end date
2019-08-31
UEI
L2T9XGZ1JUL5
Solicitation number
PA16-303
Topic code
400

Research abstract

Expressing humanized bacterial luciferase in stem cellsMoving beyond firefly luciferase toexpand the informational capacity of animal models for regenerative medicine Project Summary This Small Business Technology TransferSTTRPhase II project proposes to develop complementary autonomously bioluminescentautobioluminescentin vitro stem cell lines and in vivo small animal model systems that enable the continuousreagent freeand real time bioimaging of mesenchymal stem cellMSClocalizationdifferentiation into adipocytechondrocyteand osteocyte lineagesand persistence postdifferentiation at the site of activationThese models will specifically address the National Institutes of Health s request for new techniques for non invasivelong term tracking of stem cell survivabilityengraftmentand migration following in vivo implantationBy addressing this critical need for new methods capable of elucidating the mechanisms underlying how stem cells identify areas of dysfunction within the bodydifferentiate into the relevant tissues required to correct the maladyand persist in synergy with existing tissue to enable long term functionalitythese tools will significantly improve the transition of regenerative medicine studies towards translational and clinical practice outcomesThe autobioluminescent MSCs developed byBioTech under our Phase I effort demonstrated the ability to track MSC localization in vitro and in vivo similarly to existing optical imaging approachesbut with significantly reduced cost and personnel effortFurthermorethese models also negated the need for sample destruction or the stressful and potentially influential injection of an activating chemical concurrent with imaging while simultaneously providing an uninterrupted stream of visual data over the lifetime of the reporter cell as it interacts with its environment and undergoes differentiationIn partnership with the University of Tennessee Medical Centerthis proposal will expand upon these accomplishments to develop fully self contained autobioluminescent MSC based cellular models capable of specifically reporting on their differentiation into adipocytechondrocyteand osteocyte lineagesand complementary small animal models harboring native MSCs genetically programmed to autonomously enact their reporter functionality only following differentiation into adipocytechondrocyteor osteocyte lineages in response to wounding or exogenous stimulationThese models will overcome the primary technical hurdles encountered with all existing bioluminescent and fluorescent stem cells currently on the market from companies such as PerkinElmerThermoFisher Life TechnologiesPromegaandsmaller specialized business entities in the U Salonewhich comprise an estimated market value of at least $ Bwith a predicated annual growth rate ofWe believe that the products developed in this effort will be capable of significantly improving the throughput and effectiveness of regenerative medicine studies and advancing our understanding of stem cell based treatment efficiency and efficacy to improve both public health and consumer safetyThe functional demonstrations and data gathered in this effort will position these models to thrive within this market and produce an immediate and significant impact on the field of regenerative medicine that will benefit the population at large

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2013–2019). Reported award amounts total $5,038,908. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.